Therapeutic effect of secretin in patients with jaundice; double-blind placebo-controlled multicentric trial
| Autor: | Kiwamu Okita, Kojiro Shigeta, Takahiro Yamasaki, Tomoo Sekitani, Hiroko Tanaka, Yohzo Iida, Toshihiko Takenami, Yohei Fukumoto, Kenji Kawaguchi, Takahiro Kodama, Yoshio Harada, Michiko Kohzu, Kazuo Harima, Tomomi Konishi, Hiroshi Fujimura, Hiroyuki Shirasawa, Tetsuro Hanta, Satoyoshi Yamashita, Masakatsu Shimada, Susumu Kawamura, Shoshi Matsuda, Keijiro Andoh |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
medicine.medical_specialty Choleretic Cirrhosis Time Factors Adolescent Hepatitis Viral Human digestive system Gastroenterology Secretin Primary sclerosing cholangitis Primary biliary cirrhosis Cholestasis Double-Blind Method Liver Function Tests Liver Cirrhosis Alcoholic Internal medicine medicine Humans Aged Hepatitis business.industry Bilirubin Jaundice Middle Aged medicine.disease digestive system diseases Case-Control Studies medicine.symptom Chemical and Drug Induced Liver Injury business |
| Zdroj: | Journal of gastroenterology. 31(3) |
| ISSN: | 0944-1174 |
| Popis: | Secretin, a gastrointestinal hormone, has been shown to have a potent choleretic effect. Having already obtained some beneficial effects with secretin in patients with intrahepatic cholestasis, we sought to confirm its effects in a double-blind placebo-controlled study in patients with mild jaundice after acute or during chronic hepatitis, where total bilirubin level was in excess of 4.0 mg/dl for 3 days or more. Patients with primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and familiar hyperbilirubinemia were excluded from the study. Ninety-three patients were included in this analysis, but the final evaluation covered 69 of them. No statistically significant differences were found in the reduction of serum bilirubin levels between secretin and placebo groups. As a number of patients with liver cirrhosis had been included, the subjects were subdivided into one group with cholestasis in hepatitis and one with liver cirrhosis. In the subgroup of cirrhotic patients who received secretin, serum levels of AST were significantly increased compared with the placebo group. However, since the choleretic effect of secretin is unique, further studies seem to be warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink